TY - JOUR
T1 - Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism
AU - Patel, Parth
AU - Patel, Payal
AU - Bhatt, Meha
AU - Braun, Cody
AU - Begum, Housne
AU - Nieuwlaat, Robby
AU - Khatib, Rasha
AU - Martins, Carolina C.
AU - Zhang, Yuan
AU - Etxeandia-Ikobaltzeta, Itziar
AU - Varghese, Jamie
AU - Alturkmani, Hani
AU - Bahaj, Waled
AU - Baig, Mariam
AU - Kehar, Rohan
AU - Mustafa, Ahmad
AU - Ponnapureddy, Rakesh
AU - Sethi, Anchal
AU - Thomas, Merrill
AU - Wooldridge, David
AU - Lim, Wendy
AU - Bates, Shannon M.
AU - Lang, Eddy
AU - Le Gal, Grégoire
AU - Haramati, Linda B.
AU - Kline, Jeffrey
AU - Righini, Marc
AU - Wiercioch, Wojtek
AU - Schünemann, Holger
AU - Mustafa, Reem A.
N1 - Publisher Copyright:
© 2021 by The American Society of Hematology
PY - 2021/4/27
Y1 - 2021/4/27
N2 - Prompt evaluation and therapeutic intervention of suspected pulmonary embolism (PE) are of paramount importance for improvement in outcomes. We systematically reviewed outcomes in patients with suspected PE, including mortality, incidence of recurrent PE, major bleeding, intracranial hemorrhage, and postthrombotic sequelae. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for eligible studies, reference lists of relevant reviews, registered trials, and relevant conference proceedings. We included 22 studies with 15 865 patients. Among patients who were diagnosed with PE and discharged with anticoagulation, 3-month follow-up revealed that all-cause mortality was 5.69% (91/1599; 95% confidence interval [CI], 4.56-6.83), mortality from PE was 1.19% (19/1597; 95% CI, 0.66-1.72), recurrent venous thromboembolism (VTE) occurred in 1.38% (22/1597; 95% CI: 0.81-1.95), and major bleeding occurred in 0.90% (2/221%; 95% CI, 0-2.15). In patients with a low pretest probability (PTP) and negative D-dimer, 3-month follow-up revealed mortality from PE was 0% (0/808) and incidence of VTE was 0.37% (4/1094; 95% CI: 0.007-0.72). In patients with intermediate PTP and negative D-dimer, 3-month follow-up revealed that mortality from PE was 0% (0/2747) and incidence of VTE was 0.46% (14/3015; 95% CI: 0.22-0.71). In patients with high PTP and negative computed tomography (CT) scan, 3-month follow-up revealed mortality from PE was 0% (0/651) and incidence of VTE was 0.84% (11/1302; 95% CI: 0.35-1.34). We further summarize outcomes evaluated by various diagnostic tests and diagnostic pathways (ie, D-dimer followed by CT scan).
AB - Prompt evaluation and therapeutic intervention of suspected pulmonary embolism (PE) are of paramount importance for improvement in outcomes. We systematically reviewed outcomes in patients with suspected PE, including mortality, incidence of recurrent PE, major bleeding, intracranial hemorrhage, and postthrombotic sequelae. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase for eligible studies, reference lists of relevant reviews, registered trials, and relevant conference proceedings. We included 22 studies with 15 865 patients. Among patients who were diagnosed with PE and discharged with anticoagulation, 3-month follow-up revealed that all-cause mortality was 5.69% (91/1599; 95% confidence interval [CI], 4.56-6.83), mortality from PE was 1.19% (19/1597; 95% CI, 0.66-1.72), recurrent venous thromboembolism (VTE) occurred in 1.38% (22/1597; 95% CI: 0.81-1.95), and major bleeding occurred in 0.90% (2/221%; 95% CI, 0-2.15). In patients with a low pretest probability (PTP) and negative D-dimer, 3-month follow-up revealed mortality from PE was 0% (0/808) and incidence of VTE was 0.37% (4/1094; 95% CI: 0.007-0.72). In patients with intermediate PTP and negative D-dimer, 3-month follow-up revealed that mortality from PE was 0% (0/2747) and incidence of VTE was 0.46% (14/3015; 95% CI: 0.22-0.71). In patients with high PTP and negative computed tomography (CT) scan, 3-month follow-up revealed mortality from PE was 0% (0/651) and incidence of VTE was 0.84% (11/1302; 95% CI: 0.35-1.34). We further summarize outcomes evaluated by various diagnostic tests and diagnostic pathways (ie, D-dimer followed by CT scan).
UR - http://www.scopus.com/inward/record.url?scp=85106270183&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106270183&partnerID=8YFLogxK
U2 - 10.1182/BLOODADVANCES.2020002398
DO - 10.1182/BLOODADVANCES.2020002398
M3 - Review article
C2 - 33900385
AN - SCOPUS:85106270183
SN - 2473-9529
VL - 5
SP - 2237
EP - 2244
JO - Blood Advances
JF - Blood Advances
IS - 8
ER -